PortalPublikationenCXCR7 expression in esophageal cancer

CXCR7 expression in esophageal cancer

Standard

CXCR7 expression in esophageal cancer. / Tachezy, Michael; Zander, Hilke; Gebauer, Florian; Loga, Katharina; Pantel, Klaus; Izbicki, Jakob R; Bockhorn, Maximilian.

in: J TRANSL MED, Jahrgang 11, 01.01.2013, S. 238.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Tachezy, M, Zander, H, Gebauer, F, Loga, K, Pantel, K, Izbicki, JR & Bockhorn, M 2013, 'CXCR7 expression in esophageal cancer', J TRANSL MED, Jg. 11, S. 238. https://doi.org/10.1186/1479-5876-11-238

APA

Tachezy, M., Zander, H., Gebauer, F., Loga, K., Pantel, K., Izbicki, J. R., & Bockhorn, M. (2013). CXCR7 expression in esophageal cancer. J TRANSL MED, 11, 238. https://doi.org/10.1186/1479-5876-11-238

Vancouver

Tachezy M, Zander H, Gebauer F, Loga K, Pantel K, Izbicki JR et al. CXCR7 expression in esophageal cancer. J TRANSL MED. 2013 Jan 1;11:238. https://doi.org/10.1186/1479-5876-11-238

Bibtex

@article{610d264715414e37840d726edcaffff8,
title = "CXCR7 expression in esophageal cancer",
abstract = "BACKGROUND: The chemokine CXCL12 and its receptor CXCR4 play a major role in tumor invasion, proliferation and metastasis in different malignant diseases, including esophageal carcinoma, amongst others. CXCR7 was recently identified as a novel alternate receptor for CXCL12. The aim of this study was to evaluate the prognostic impact of expression of chemokine receptor CXCR7 in patients with esophageal carcinoma (EC).METHODS: Expression of CXCR7 in primary tumors, lymph nodes and distant metastases of 299 patients with EC was evaluated by immunohistochemistry on a tissue microarray and compared with clinical and histopathological data.RESULTS: In esophageal cancer sections, CXCR7-specific reactivity was apparent in 45% of the squamous cell carcinomas (ESCC), but only occasionally in adenocarcinomas. No correlation between CXCR4 and CXCR7 expression was evident. We correlated expression with clinical and histopathological characteristics, but could not find any association.CONCLUSIONS: Contrary to the other known CXCL12 receptor, CXCR4, CXCR7 is expressed in ESCC only, underlining the divergent mechanisms and backgrounds of EAC and ESCC. The results of the study do not indicate a significant functional role for CXCR7 in EAC or ESCC of the esophagus. However, its variable expression in the main two main types of EC needs to be further investigated.",
author = "Michael Tachezy and Hilke Zander and Florian Gebauer and Katharina Loga and Klaus Pantel and Izbicki, {Jakob R} and Maximilian Bockhorn",
year = "2013",
month = jan,
day = "1",
doi = "10.1186/1479-5876-11-238",
language = "English",
volume = "11",
pages = "238",
journal = "J TRANSL MED",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - CXCR7 expression in esophageal cancer

AU - Tachezy, Michael

AU - Zander, Hilke

AU - Gebauer, Florian

AU - Loga, Katharina

AU - Pantel, Klaus

AU - Izbicki, Jakob R

AU - Bockhorn, Maximilian

PY - 2013/1/1

Y1 - 2013/1/1

N2 - BACKGROUND: The chemokine CXCL12 and its receptor CXCR4 play a major role in tumor invasion, proliferation and metastasis in different malignant diseases, including esophageal carcinoma, amongst others. CXCR7 was recently identified as a novel alternate receptor for CXCL12. The aim of this study was to evaluate the prognostic impact of expression of chemokine receptor CXCR7 in patients with esophageal carcinoma (EC).METHODS: Expression of CXCR7 in primary tumors, lymph nodes and distant metastases of 299 patients with EC was evaluated by immunohistochemistry on a tissue microarray and compared with clinical and histopathological data.RESULTS: In esophageal cancer sections, CXCR7-specific reactivity was apparent in 45% of the squamous cell carcinomas (ESCC), but only occasionally in adenocarcinomas. No correlation between CXCR4 and CXCR7 expression was evident. We correlated expression with clinical and histopathological characteristics, but could not find any association.CONCLUSIONS: Contrary to the other known CXCL12 receptor, CXCR4, CXCR7 is expressed in ESCC only, underlining the divergent mechanisms and backgrounds of EAC and ESCC. The results of the study do not indicate a significant functional role for CXCR7 in EAC or ESCC of the esophagus. However, its variable expression in the main two main types of EC needs to be further investigated.

AB - BACKGROUND: The chemokine CXCL12 and its receptor CXCR4 play a major role in tumor invasion, proliferation and metastasis in different malignant diseases, including esophageal carcinoma, amongst others. CXCR7 was recently identified as a novel alternate receptor for CXCL12. The aim of this study was to evaluate the prognostic impact of expression of chemokine receptor CXCR7 in patients with esophageal carcinoma (EC).METHODS: Expression of CXCR7 in primary tumors, lymph nodes and distant metastases of 299 patients with EC was evaluated by immunohistochemistry on a tissue microarray and compared with clinical and histopathological data.RESULTS: In esophageal cancer sections, CXCR7-specific reactivity was apparent in 45% of the squamous cell carcinomas (ESCC), but only occasionally in adenocarcinomas. No correlation between CXCR4 and CXCR7 expression was evident. We correlated expression with clinical and histopathological characteristics, but could not find any association.CONCLUSIONS: Contrary to the other known CXCL12 receptor, CXCR4, CXCR7 is expressed in ESCC only, underlining the divergent mechanisms and backgrounds of EAC and ESCC. The results of the study do not indicate a significant functional role for CXCR7 in EAC or ESCC of the esophagus. However, its variable expression in the main two main types of EC needs to be further investigated.

U2 - 10.1186/1479-5876-11-238

DO - 10.1186/1479-5876-11-238

M3 - SCORING: Journal article

C2 - 24074251

VL - 11

SP - 238

JO - J TRANSL MED

JF - J TRANSL MED

SN - 1479-5876

ER -